A Phase Ib Open-Label, Dose-Escalation Study of the Safety and Pharmacology of GDC-0032 in Combination With Either Docetaxel or Paclitaxel in Patients With HER2-Negative, Locally Advanced or Metastatic Breast Cancer or Non-Small Cell Lung Cancer
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 16 May 2017
At a glance
- Drugs Taselisib (Primary) ; Docetaxel; Paclitaxel
- Indications Breast cancer; Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Genentech
- 07 Jun 2017 Biomarkers information updated
- 09 May 2017 Planned End Date changed from 1 Dec 2017 to 4 Oct 2017.
- 09 May 2017 Planned primary completion date changed from 1 Dec 2017 to 4 Oct 2017.